Articles tagged with Lung Cancer
Researchers found significant cell changes in workers exposed to hexavalent chromium at levels below Sweden's current limit. The study suggests the need for stricter safety regulations and lower limits for this carcinogenic substance.
A new study by Mass General Brigham researchers reveals that many eligible patients who receive other preventative screenings are not getting screened for lung cancer. The study found that 65% of those eligible received breast and colorectal cancer screening, a nearly 4-fold higher rate than lung cancer screening.
Researchers discovered TBX2 drives therapy resistance by shifting signaling from the androgen receptor to the glucocorticoid receptor. The study identified a strategy to target this switch, potentially predicting patient risk and offering new treatment approaches.
Researchers at MD Anderson Cancer Center made several key discoveries, including the spatial organization of cancer-associated fibroblasts across various cancers and a study on treatment resistance in SMARCA4-mutant lung cancer. These findings highlight the importance of investigating cell populations in their spatial context to better...
A new study published by the American Cancer Society estimates that tobacco control measures have averted over 3.8 million lung cancer deaths and gained 76 million years of life in the US between 1970 and 2022. The study highlights the significant impact of progress against smoking on reducing premature mortality from lung cancer.
A study published in the British Journal of General Practice found a significant link between chest x-ray referrals and earlier lung cancer diagnosis and better survival rates. Patients attending practices with high chest x-ray usage were more likely to be diagnosed at an earlier stage, leading to improved survival rates.
Dr. John Turchi, a leading lung cancer researcher, has been appointed as the inaugural executive director of the Tom and Julie Wood Center for Lung Cancer Research at Indiana University. The center aims to advance lung cancer research and improve patient outcomes through innovative therapies and personalized care.
A new editorial highlights a growing concern in cancer care: radiotherapy may leave behind residual disease that can lead to worse long-term outcomes. Studies have shown that patients with residual disease are more likely to experience cancer recurrence and shorter survival, emphasizing the need for regular biopsy-based tests.
New leukemia treatment combination shows promise for patients with follicular lymphoma. Immunotherapy research also explores ways to suppress protein ZNF638 to boost effectiveness of immune checkpoint inhibitors. Innovative funding efforts support Sylvester's cancer research initiatives.
The updated guidelines substantially increased lung cancer screenings overall, but disparities persist among people with limited access to healthcare. Barriers include cost, knowledge, and lack of primary care providers, with mobile units and patient navigators offering potential solutions.
The European Lung Cancer Congress 2025 will take place in Paris from March 26-29, featuring renowned experts discussing the latest research on lung cancer prevention, diagnosis, and treatment. The congress will also include award lectures and live streaming of the event.
A multicenter cohort study found that higher adherence to annual lung cancer screening was associated with increased overall and early-stage lung cancer detection rates. However, adherence decreased over time, suggesting it is a critical quality metric for lung cancer screening.
This cohort study found that geographic access to cancer care is associated with guideline-recommended treatment for early-stage non–small cell lung cancer. Socially marginalized patients benefited from improved treatment outcomes and prognosis when accessing care in their local area.
A post-treatment blood test measures cancer-derived molecules in patients with lung cancer years after treatment. This tool can inform clinical intervention, including restarting or intensifying treatment for high-risk patients.
Researchers found that a Western-style diet high in glycogen can fuel lung cancer tumors, leading to faster growth and worse outcomes. A nutrient-rich diet, active lifestyle, and reduced alcohol intake are recommended for lung cancer prevention.
Breast cancer death rates are predicted to increase in EU patients aged 80 years and older, while falling in all other age groups. This is attributed to a lack of regular screening and access to modern treatments.
Scientists at VCU Massey Comprehensive Cancer Center have discovered a powerful combination therapy that leverages sotorasib and FGTI-2734 to tackle drug resistance in lung cancer. The treatment targets the KRAS G12C mutation, which is responsible for about 14% of non-small cell lung cancers.
A study of nearly 2,500 postmenopausal women found that taking more daily steps and engaging in moderate-to-vigorous physical activity were associated with a significantly reduced risk of death from cardiovascular disease. Even walking fewer than 5,000 steps per day showed a risk reduction.
Short-course corticosteroid treatment was associated with lower surgical site complications and in-hospital mortality in patients with postoperative acute lung injury following lung resection surgery. The optimal duration of corticosteroid treatment remains uncertain, highlighting the need to weigh benefits against adverse effects.
Researchers at Tufts University have developed a cancer vaccine that amplifies the visibility of tumor antigens to the immune system, leading to potent responses and lasting immunological memory. The vaccine works against multiple solid tumors in animal models, including melanoma, triple-negative breast cancer, and ovarian cancer.
The hybrid operating room enables the entire procedure to be performed in a single step, allowing for more precise positioning of the thoracic endoprosthesis. This approach requires collaboration between thoracic surgeons and vascular surgeons.
A new laser-based device can analyze gas samples with high precision, detecting molecules at minute concentrations. The technology has potential applications in medical diagnostics, tracking greenhouse gas emissions, and more.
Cancer cells work together to source nutrients from their environment, a cooperative process that can be targeted for treating cancer. Researchers identified key enzymes and mechanisms behind this cooperation, including the enzyme CNDP2, which can be inhibited by the drug bestatin.
The Lung Cancer Research Foundation and Israel Cancer Research Fund are partnering to test an innovative new treatment for lung cancer. The project aims to explore the effects of a drug that targets IGF2BP1, a protein involved in cancer cell growth.
A study found that 77.9% of lung cancer patients had detectable atherosclerosis on CT scans, with smoking being the most prominent cardiac risk factor. The results suggest using concurrent coronary calcium scoring to aid in identification and earlier intervention for these patients.
The study reveals that certain DNA regions are more prone to damage but also better repaired by cells. Transcription factors can either help or harm DNA, highlighting the importance of efficient repair in determining mutation formation.
A study found that MAGE-4 drives the accumulation of plasma immune cells suppressing antitumor immunity in mouse and human non-small cell lung cancer models. The protein promotes tumor progression by losing a tumor suppressor gene, PTEN, accelerating development into metastasis.
Researchers at University of California, Merced are using wastewater-based epidemiology to track nicotine use in San Joaquin Valley communities. The project aims to determine trends and levels of nicotine use through chemicals in wastewater, providing valuable insights for public health agencies and tobacco-control researchers.
Scientists have pinpointed a weakness in lung cancer's defenses by uncovering an enzyme that boosts cancer cell metabolism to fuel growth. Researchers identified GUK1 as a metabolic enzyme that plays a crucial role in ALK-positive cancers, suggesting it may be a target for new therapies.
The Micro Immune Response On chip (MIRO) replicates tumours and their environment, allowing researchers to study the efficacy of immunotherapy treatments. This technology has been tested with breast cancer samples and shows promise in understanding how the immune system interacts with tumours.
A new genetic mutation, RUFY1-RET fusion, was discovered in a patient with stage IV CD-74-ROS1 fusion NSCLC who developed resistance to lorlatinib. The finding highlights the importance of ongoing genetic testing to guide therapy decisions.
A new low-cost, fast response sensor has been developed to detect lung cancer biomarkers, enabling early diagnosis and improved patient outcomes. The technology can identify patients at higher risk of lung cancer and tailor treatments for those already diagnosed.
Researchers developed a computer model called MANAscore to identify tumor-fighting immune cells in lung cancer patients treated with immune checkpoint inhibitors. The three-gene model helped find differences associated with patient response to immunotherapy, including the presence of stem-like memory T cells.
Researchers at H. Lee Moffitt Cancer Center discovered a biomarker that can predict which lung cancer patients with KRASG12C mutation are most likely to benefit from targeted treatments. The study found that tumors with higher levels of RAS-RAF protein interaction respond better to KRASG12C inhibitors.
The addition of da Vinci 5 robotic surgical systems at Huntsman Cancer Institute offers enhanced precision and control during minimally invasive surgeries. The system's advanced technology enables complex procedures to be performed through small incisions, reducing hospital stays and accelerating recovery times for patients.
The study analyzed 63 tumor samples from 10 common malignancies, revealing how malignant cells specialize in growing tumors and non-cancer cells contribute to the immune system's suppression. The findings suggest a hierarchical structure of tumors with specific hallmark expression patterns.
A pooled data analysis found that cancer chemotherapy is linked to persistent severe peripheral nerve pain for around 4 in every 10 patients, with platinum-based drugs and taxanes associated with the highest rates of painful neuropathy. The study analyzed data from 77 eligible studies involving 10,962 participants from 28 countries.
Research presented at the 2025 STS Annual Meeting reveals that anatomic lung resections such as lobectomy and segmentectomy are associated with improved long-term survival compared to wedge resection for stage 1A NSCLC. Lobectomy offered the highest survival rates, with a 71.9% 5-year OS and 44.8% 10-year OS.
The Chris Chang Lab develops a copper-detection tool to uncover how copper regulates cell growth in lung cancer. The probe identifies cells with elevated copper levels and reveals a connection between copper and the antioxidant response mediated by NRF2.
A new deep learning model has been developed to detect and segment lung tumors on CT scans with high accuracy. The model achieved 92% sensitivity and 82% specificity in detecting lung tumors, outperforming physician-delineated volumes in some cases. However, further research is needed to improve the model's performance for larger tumors.
The FDA has revoked authorization for the use of Red Dye 3 in food and ingested drugs, citing studies linking it to cancer in laboratory male rats. This decision is an important step forward in addressing modifiable risk factors that have the potential to reduce cancer risk.
A recent study found that U.S. soldiers are 10 times more likely to use nicotine pouches, which can cause serious health issues, compared to the general population. The study analyzed anonymous responses from 1,957 soldiers and found that 23.8% reported using nicotine pouches in the previous 30 days.
A new test detecting tiny fragments of DNA in blood plasma can predict lung cancer relapse and overall survival. Patients with low levels of tumor DNA before surgery have improved survival rates, while those with high levels are more likely to relapse.
A cross-sectional study found that American Indian/Alaska Native populations are significantly farther away from lung cancer screening centers than non-Hispanic White populations. The researchers recommend increasing access to lung cancer services through mobile units and imaging locations to address these disparities.
A new study found that Medicare Advantage patients with colorectal cancer are six percentage points less likely to receive a cancer drug compared to those on Traditional Medicare. For non-small cell lung cancer, the pattern was not as clear due to limited low-cost treatment options.
A new test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used clinical risk factors. This could help doctors make more informed treatment decisions for people with stage 1 lung cancer, potentially improving patient outcomes.
A new study found that while lung cancer deaths decreased globally from 1990 to 2019, mortality linked to tobacco use and air pollution increased. Tobacco remains the leading cause of death, accounting for 66% of TBL cancer deaths in 2019, while particulate matter pollution is a growing concern.
Researchers developed a novel inhalable therapeutic delivery system for lung cancer using mucoadhesive protein nanoparticles inspired by marine mussels. The approach leverages the adhesive properties of mussel proteins to enable selective payload release and minimize adverse effects.
Researchers have developed a way to detect circulating tumor cells in the bloodstream using biolasers, which can provide valuable information about the DNA organization inside cancer cells. The technique has been successfully tested on pancreatic and lung cancer patients, showing high accuracy rates of up to 99%.
The study found that high levels of aspartate in the lungs are associated with aggressive lung metastases, triggered by an alternative translation program driven by aspartate signaling. This discovery suggests a common feature of cancer cells growing in the lung and provides a potential target for new therapeutic interventions.
Researchers discovered that blocking cell cycle inhibitor p21 prevents lung cancer cells from entering a quiescent state, allowing for more cancer cell death before and after chemotherapy. This leads to reduced cancer relapse rates, improving patient outcomes.
A review of 3,000 studies suggests microplastics in the air may cause serious health problems, including colon cancer, poor lung function, and infertility. The tiny plastic particles are believed to contribute to chronic pulmonary inflammation, increasing the risk of lung cancer.
A new diagnostic test uses a unique molecular 'finger print' to detect different types of cancer, with near-perfect accuracy, and could lead to earlier detection and improved patient outcomes. The test targets ribosomal RNA molecules, which are modified differently in healthy and diseased tissues.
Researchers combine a precision cancer drug with an antibody and radiation therapy to eliminate tumors without causing side effects. The approach uses the cancer drug as a molecular flag for cancerous cells, allowing immune cells to target them. This method has shown promise in eliminating lung cancer in mice with minimal side effects.
The study found that smokers with myelodysplastic syndromes (MDS) or precursor conditions had elevated levels of genetic mutations linked to the disease. Heavier smokers accumulated more mutations, and long-term smokers were more likely to show disease progression.
A national lung cancer screening program is proposed to reduce deaths and improve survival rates for Australian patients. The Flinders University study found that screening individuals aged 50-70 every two years would be cost-effective and add significant years of healthy life.
The study estimated that prevention, screening, and treatment efforts in the US led to an average of 8 out of 10 cancer deaths being avoided for breast, cervical, colorectal, lung, and prostate cancers combined. The total number of averted cancer deaths was approximately 5.94 million between 1975 and 2020.
The PoweRD 2 Cure ALK+ Lung Cancer TeamLab aims to identify and exploit vulnerabilities of leftover cancer cells to prevent recurrence. By combining new strategies, structures, and thinking from across disciplines, researchers hope to develop treatment strategies that leave no cancer cells alive.
The global lifetime risk of lung cancer is 3.49%, with high-risk countries like French New Caledonia and Canada, while low-HDI countries have lower risks due to shorter lifespans and limited resources. After 40, the risk drastically increases, but residual risk decreases with age.
Researchers found that as cells age, they lose regenerative capacity and become less susceptible to cancer. The study's findings suggest that therapies targeting ferroptosis may be less effective in older patients.